Received Oct 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (NO BRAND NAME) | UNKNOWN MANUFACTURER | 4 | UNK | — |
DTaP missed fourth and fifth dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incomplete course of vaccination in a female patient who did not receive DTPa (DTPa vaccine) for prophylaxis. Previously administered products included Pediarix (1st dose received in 2020), Tetraxim (2nd dose received in 2022) and Vaxelis (3rd dose received in 2024). On an unknown date, the patient did not receive the 4th dose of DTPa vaccine. The patient experienced incomplete course of vaccination (Verbatim: DTaP missed fourth and fifth dose). The outcome of the incomplete course of vaccination was not applicable. Additional Information: GSK Receipt Date: 16-SEP-2025 A health care provider asked if she could administer Boostrix to an 8-year-old patient that was behind in the DTaP schedule (receiving so far one dose of DTaP-IPV-HepB in 2020, one of DTaP-IPV in 2022 and another DTaP-IPV-HepB in 2024. The batch number was not provided and a request for this information has been made.